Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707533 | 1.00 | NPC1 (0.53) | NPC1RAB9AKMT2AMEN1ATM | |
| SCHEMBL5689431 | 0.75 | MAOB (0.75) | NPC1RAB9AMAOBMAOAPTPN1 | |
| SCHEMBL2559162 | 0.74 | MAPT (0.57) | KMT2AMEN1MAOBMAOAPTPN1 | |
| SCHEMBL2559161 | 0.74 | MAPT (0.57) | KMT2AMEN1MAOBMAOAPTPN1 | |
| SCHEMBL229328 | 0.73 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1ATM | |
| SCHEMBL12903098 | 0.73 | MAOB (0.50) | MAOBMAOAPTPN1KDM4EMAPT | |
| SCHEMBL9394256 | 0.73 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1ATM | |
| SCHEMBL9110245 | 0.73 | MAOB (0.50) | KMT2AMEN1MAOBMAOAPTPN1 | |
| SCHEMBL19275439 | 0.73 | MAOB (0.50) | MAOBMAOAPTPN1KDM4EMAPT | |
| SCHEMBL229329 | 0.73 | NPC1 (1.00) | NPC1RAB9AKMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | NPC1 19/4885RAB9A 4723/4885KMT2A 3382/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | NPC1 48/4885RAB9A 4606/4885KMT2A 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.